Developing Next Generation Psychedelic Medicines to Treat Mental Illness

Lophora is a clinical-stage CNS drug discovery company developing novel, next-generation, rapid-acting medicines to treat neurological and psychiatric disorders, such as depressive, anxiety, eating, and mood disorders, PTSD, and substance use disorders.

About us

The company has identified and patented a new class of proprietary ligands. The lead compound LPH-5 is a highly selective small-molecule agonist of the Serotonin HT2AR and exhibits robust CNS exposure, target engagement and efficacy in animal models of depression. LPH-5 successfully completed IND enabling GLP Tox studies in Q4 2022 and is now advancing to Phase I.

Lophora Founders Team at BioInnovation Institute (October 2020). From left: Emil Märcher-Rørsted, Jesper Langgaard Kristensen, Bo Tandrup, Anders Asbjørn Jensen.

News

Lophora Successfully Completes $3M Financing to Propel Phase I Trials for Lead CNS Drug LPH-5

After receiving approval from the European Medicines Agency (EMA) to commence its Phase I clinical study for LPH-5, Lophora has

January 15, 2025

Lophora Receives Approval from EMA to Initiate Phase I Clinical Trial for LPH-5, a Promising Treatment for Depression.

Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2AR therapeutics to treat psychiatric disorders, announced today that

September 17, 2024

Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for lead CNS drug LPH-5.

Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA medicines to treat a multitude of psychiatric disorders,

May 31, 2024

Structure-Activity Relationships of Lophora’s selective serotonin 5-HT2A receptor agonists published in the Journal of Medicinal Chemistry

The Lophora team has published a paper detailing the discovery and structure of the lead clinical candidate LPH-5 in the

May 3, 2024

Lophora Closes Bridge Round to Strengthen Global Patent Portfolio and prepare for Phase I

Founded by initial investments from BII (Novo Nordisk Foundation), Vækstfonden (EIFO) and Innovation Fund Denmark, Lophora has received additional support

August 24, 2023

Lophora completes preclinical development of LPH-5 for treatment-resistant depression

Lophora has completed the pre-clinical development of its first-in-class lead candidate LPH-5 for Treatment Resistant Depression. No toxicology or histopathology

November 22, 2022

Developing Next Generation Psychedelic Medicines to Treat Mental Illness

About us

News

Get Exclusive Updates from Lophora – Subscribe to Our Newsletter